Qiagen to Post Q1 2024 Earnings of $0.43 Per Share, William Blair Forecasts (NYSE:QGEN)

Qiagen (NYSE:QGENFree Report) – Research analysts at William Blair dropped their Q1 2024 earnings estimates for Qiagen in a research report issued on Wednesday, February 7th. William Blair analyst A. Brackmann now expects that the company will post earnings per share of $0.43 for the quarter, down from their previous estimate of $0.50. The consensus estimate for Qiagen’s current full-year earnings is $2.10 per share. William Blair also issued estimates for Qiagen’s Q2 2024 earnings at $0.53 EPS, Q3 2024 earnings at $0.55 EPS, FY2024 earnings at $2.09 EPS, Q1 2025 earnings at $0.50 EPS, Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.57 EPS, Q4 2025 earnings at $0.61 EPS and FY2025 earnings at $2.25 EPS.

Other equities research analysts also recently issued research reports about the stock. Wolfe Research initiated coverage on shares of Qiagen in a research note on Wednesday, December 13th. They set a “peer perform” rating on the stock. Citigroup reduced their target price on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a research note on Thursday. The Goldman Sachs Group upgraded shares of Qiagen from a “neutral” rating to a “buy” rating and set a $51.55 target price on the stock in a research note on Thursday, December 7th. UBS Group reduced their target price on shares of Qiagen from $49.48 to $43.30 and set a “neutral” rating on the stock in a research note on Thursday, November 2nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Qiagen currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.79.

Get Our Latest Stock Report on QGEN

Qiagen Stock Up 0.8 %

QGEN opened at $44.48 on Friday. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $49.26. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.74 and a quick ratio of 2.98. The firm’s fifty day moving average price is $44.66 and its two-hundred day moving average price is $43.35. The company has a market capitalization of $9.84 billion, a P/E ratio of 29.40, a P/E/G ratio of 15.94 and a beta of 0.43.

Qiagen (NYSE:QGENGet Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.55 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.55. Qiagen had a net margin of 17.37% and a return on equity of 13.15%. The firm had revenue of $509.00 million for the quarter, compared to the consensus estimate of $500.77 million. During the same quarter in the previous year, the company earned $0.53 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Norges Bank bought a new stake in Qiagen during the 4th quarter worth about $264,322,000. Wellington Management Group LLP raised its holdings in Qiagen by 81.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company’s stock worth $245,299,000 after purchasing an additional 2,709,030 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Qiagen by 8.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock worth $1,045,211,000 after purchasing an additional 1,809,486 shares during the last quarter. Earnest Partners LLC grew its position in shares of Qiagen by 925,843.4% during the 2nd quarter. Earnest Partners LLC now owns 1,407,434 shares of the company’s stock worth $63,377,000 after buying an additional 1,407,282 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Qiagen by 33,220.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,345,488 shares of the company’s stock worth $58,435,000 after buying an additional 1,341,450 shares during the period. 57.99% of the stock is owned by institutional investors.

Qiagen Announces Dividend

The firm also recently declared a — dividend, which was paid on Tuesday, January 30th. Investors of record on Wednesday, January 31st were issued a $1.3196 dividend. The ex-dividend date of this dividend was Tuesday, January 30th.

About Qiagen

(Get Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Featured Stories

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.